加载中
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
常规交易时段
US$23.415
−US$0.925 · -3.80%
盘中时间采用ET。市场数据可能有所延迟。
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
日内区间
当前US$23.415
52周区间
当前US$23.415
盘中时间采用ET。市场数据可能有所延迟。
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
日内区间
当前US$23.415
52周区间
当前US$23.415
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.47亿 USD | 2.58亿 USD | 1.17亿 USD | 1.12亿 USD | 3.83亿 USD |
| 销货成本 | 1000万 USD | — | — | — | — |
| 毛利 | 2.37亿 USD | 2.58亿 USD | 1.17亿 USD | 1.12亿 USD | 3.83亿 USD |
| 研究与开发 | 5.23亿 USD | 4.48亿 USD | 3.4亿 USD | 2.88亿 USD | 2.57亿 USD |
| 销售、一般及管理费用 | 1.1亿 USD | 1.2亿 USD | 1.17亿 USD | 1.04亿 USD | 7200万 USD |
| 营业费用 | 6.23亿 USD | 5.88亿 USD | 4.57亿 USD | 3.92亿 USD | 3.29亿 USD |
| 利息收入 | 4100万 USD | 5200万 USD | 4100万 USD | 1600万 USD | 100万 USD |
| 利息支出 | 800万 USD | 400万 USD | 200万 USD | 200万 USD | — |
| 折旧和摊销 | 1000万 USD | 1000万 USD | 800万 USD | 600万 USD | 400万 USD |
| 营业利润 | −3.86亿 USD | −3.3亿 USD | −3.4亿 USD | −2.8亿 USD | 5400万 USD |
| 净利润 | −3.53亿 USD | −2.83亿 USD | −3.07亿 USD | −2.67亿 USD | 5300万 USD |
公司数据更新于 2026年10月13日。
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI8220.35万0.00%2.3万亿 USD0.03%US$380.91-0.17%
iShares Russell 2000 ETFIWM5603.58万0.07%787.4亿 USD0.19%US$276.26-0.59%
State Street SPDR S&P Biotech ETFXBI4977.16万0.50%103.03亿 USD0.35%US$148.86-1.68%
Vanguard Morningstar Small-Cap ETFVB2963.13万0.02%1853亿 USD0.03%US$286.84-0.46%
Vanguard Extended Market ETFVXF2949.21万0.03%954亿 USD0.05%US$231.81-0.73%
Invesco S&P SmallCap Momentum ETFXSMO2191.09万0.76%28.69亿 USD0.35%US$80.74-0.70%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM2021.42万0.13%157.12亿 USD0.03%US$53.215-0.38%
Vanguard Morningstar Small-Cap Growth ETFVBK1697.87万0.04%447亿 USD0.05%US$337.42-1.02%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFInvesco S&P SmallCap Momentum ETFXSMOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMVanguard Morningstar Small-Cap Growth ETFVBKAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
